This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2026
Thank you for joining us and welcome to the Hinge Health third quarter 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press star 9 to raise your hand and star 6 to unmute. I will now hand the conference over to Bianca Buck, Head of Investor Relations. Bianca, please go ahead.
Good afternoon and welcome to Hinge Health's third quarter 2026 earnings call. I'm Bianca Buck, Head of Investor Relations. With me on the call are Daniel Perez, our co-founder and CEO, Jim Pursley, our president, Aaron Peer, our Chief Commercial Officer, and James Budge, our CFO. I want to thank everyone for joining us. As a reminder, this conference call is being recorded. All relevant materials are available on the Investor Relations section of our website. Today's discussion will include forward-looking statements, which are subject to various risks, uncertainties, and assumptions. These statements reflect our current views and expectations regarding future events, including expected performance of our business, future financial results, and growth strategies. Thank you. Thank you. We expect to file our next quarterly report on Form 10Q in the next week. All income statement financial measures discussed today, other than revenue, are non-GAAP. These measures should be viewed in addition to and not as a substitute for our GAAP results. Reconciliations to the most comparable GAAP measures are included in the appendix to our earnings release. With that, I'll turn it over to Dan.
Thanks, Bianca. Q3 was another strong proof point that automated care delivery works for our members, our clients, our partners, and our financials. Here's what I'll cover today. First, a quick snapshot of our Q3 financial performance and the momentum we're carrying. Second, a product update, what's working in our core MSK business, some early data from our migraine care program, and I want to spend a few moments on what our GI care program is going to look like, since I know that's been a common question. Third, I'll hand it to Jim and Erin for the commercial update, and Jim has a personal note he'd like to share as well. And lastly, James will take us through the financials and updated guidance before we open it up for questions. Before I begin, apologies for my hoarse voice. I'm fighting a cold, but we've got great numbers to report. Let's dive in. Q3 saw strong top-line performance and all-time highs on profitability. Revenue came in at $235 million, up 52% from $154 million in Q3 of last year. Last 12 months, calculated billings were strong as well, up 54% year over year to $960 million. Gross margin came in at 88%, up about 480 basis points from the same period last year. On the bottom line, operating income came in at $77 million, a 33% operating margin, up about 1,300 basis points year over year. Free cash flow, excluding one-time acquisition-related payments, was $120 million, representing a 51% free cash flow margin. As you can see, the momentum we saw in the first half of the year has continued, and that's a testament to the team, product, and business we've built. Let me now turn to product. Let's start with our core MSK product, where we've spent over a decade automating care and continue to see progress. A good example is movement analysis, which uses our true motion technology to give members a quantitative, objective way to track their progress, and it's being used by more and more of our members. It scores them across joint angles, symmetry, and endurance, and gives them hinge scores so they can actually see how they're improving over time, We believe that when people can see their progress in real numbers, they adhere better. We also began rolling out a redesigned exercise experience this quarter with new exercises that load faster, preview clips that show members what's coming, and a new control bar that puts them in charge of their session. These might sound like small things, but they're critical to ensuring a consumer-grade product experience, why we're the top rated digital MSK app, and something people want to open rather than feel they have to. for our MSK product is also what lets us add care for new conditions like migraine and GI efficiently. We've built an extensible platform and we believe this unified approach is a meaningful advantage for us in the market. Speaking of our new programs, let me turn to our migraine care program. We're still in early access with clients, but the data we're seeing is genuinely exciting. Initial results of our surveyed members show a 23% reduction in monthly migraine days. And when migraines did occur, members reported they were shorter by roughly five hours or a 28% reduction in the duration of the attack. We're also seeing a meaningful reduction in monthly prescription use days, which matters both for members and for the clients paying for their care. We're also tracking hit six scores. That's a validated six-item measure used widely in migraine research that captures what migraine actually takes away from someone. That is their ability to focus, work, stay present, and get through their day. About two-thirds of our members improved their hit six score, and just over half crossed the threshold for a clinically meaningful change. That's a really strong early signal, and we're looking forward to sharing more as the program scales. Thirdly, many of you have asked what our GI care program will eventually look like in the unified offering. So let me walk you through it. It's the same playbook we've run in MSK and Migraine. We start with the member intake, create a personalized care program, apply technology to automate care delivery, supplement the technology with access to clinicians and connected hardware when applicable, and hold it all to the same clinical rigor as our other programs. Fortunately, our acquisition of Cylinder and the incredible team that built it has given us a big head start. Nearly one in two people with GI conditions also have MSK pain and 70% of people with migraine also have a GI condition. These conditions are connected and most people can't always tell how. With Hinge Health, we make it easy. When a member opens a Hinge Health app, our AI-powered intake screener, the same engine that triages MSK and migraine members today, routes them to the right care automatically. Back pain, pelvic floor conditions, migraine, GI, or all of the above. Our GI care program itself will have two main parts. First, AI that turns raw signals into action, including personalized care plans. Our food analysis model can read what's going into the gut from a photo, a voice note, or a text. Robin, our AI care assistant, connects that input to symptoms in real time. And with our AI-powered stool scan, a member could capture a photo and our technology analyzes stool according to the Bristol Stool Scale, capturing form, consistency, and volume, giving us a structured longitudinal data set that both our models and our clinicians can act on. Those signals feed personalized care plans that evolve as our model learns what's driving someone's symptoms. Second, immediate access to a multidisciplinary care team from day one. No referral needed. That means a GI specialist who could prescribe and make in-person referrals when needed, a dietician focused on triggers and nutrition, and a gut brain therapist delivering cognitive behavioral therapy, which is the evidence-based standard of care for IBS. Moreover, one of the top referrals for GI symptoms is pelvic floor therapy, and we're the only GI solution with that embedded in the same app available the same day. We're really excited about where this is headed, and we think our integrated vision is differentiated. The full integrated program is targeted for the summer of 2027. We're selling the existing GI care program today, and we plan to upgrade those clients when the integrated version is ready. We expect meaningful growths in revenue contribution to come in 2028 once we've had a full 2027 selling season with the integrated program. While I love where Migraine and GI are headed, I want to remind everyone that Core MSK is still our largest revenue contributor by a wide margin, is growing robustly, and we expect it to remain that way for years to come. The opportunity in MSK remains massively underpenetrated, and everything we're doing in Migraine and GI is built on the foundation of what we've achieved in MSK. With that, I'll hand it over to Jim. Jim joined us in 2021 and has helped take us from a couple hundred clients to over 3,200 and to partnerships with 60 plus health plans, PBMs, and TPAs. That distribution model is the second wall of our moat, and much of it was built under Jim and Erin's leadership. Jim, over to you.
You're reading a preview of the HNGE Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing